Dual inhibition improves HSP90-based therapies by (i) abrogating the HSR under HSP90 inhibition, (ii) more efficient degradation of HSP90 clients, and (iii) additional positive effects from the p53 tumor-suppressive program or from cell cycle arrest. This evidence concerns the gene HSP90AB1 and neoplasm.